Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

BCAX

Bicara Therapeutics Inc

Nov 03 • 04:00PM ET

15.98

-0.27 -1.66 %

Healthcare • Biotechnology • USA • NASD

Held by: VTI IWM VXF IWN VTWO SCHA FESM VHT ITOT TMSL

Index	RUT	P/E	-	EPS (ttm)	-1.89	Insider Own	43.26%	Shs Outstand	54.56M	Perf Week	-6.00%
Market Cap	872.70M	Forward P/E	-	EPS next Y	-2.62	Insider Trans	-0.89%	Shs Float	30.99M	Perf Month	-6.22%
Enterprise Value	438.33M	PEG	-	EPS next Q	-0.54	Inst Own	64.08%	Short Float	18.33%	Perf Quarter	40.67%
Income	-102.67M	P/S	-	EPS this Y	43.65%	Inst Trans	-2.58%	Short Ratio	10.88	Perf Half Y	14.14%
Sales	0.00M	P/B	2.00	EPS next Y	-14.90%	ROA	-31.00%	Short Interest	5.68M	Perf YTD	-8.27%
Book/sh	7.98	P/C	2.00	EPS next 5Y	14.24%	ROE	-32.71%	52W High	28.09 -43.11%	Perf Year	-32.57%
Cash/sh	7.99	P/FCF	-	EPS past 3/5Y	-30.70% -	ROIC	-23.53%	52W Low	7.80 104.87%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.75% 7.67%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	1.24	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	25.80	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	48.93	Recom	1.22
Dividend Gr. 3/5Y	- -	Current Ratio	25.80	EPS Q/Q	-60.29%	SMA20	-7.70%	Beta	-0.75	Target Price	32.14
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	10.70%	Rel Volume	1.14	Prev Close	16.25
Employees	55	LT Debt/Eq	0.00	Earnings	Aug 12 BMO	SMA200	26.75%	Avg Volume	522.19K	Price	15.98
IPO	Sep 13, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	9.75% -	Trades		Volume	594,095	Change	-1.66%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-19-25	Initiated	Piper Sandler	Overweight	$36
May-23-25	Upgrade	Wells Fargo	Underweight → Equal Weight	$8
Apr-17-25	Initiated	Wells Fargo	Underweight	$8
Feb-06-25	Initiated	Wedbush	Outperform	$31
Dec-06-24	Initiated	H.C. Wainwright	Buy	$42
Nov-05-24	Initiated	Rodman & Renshaw	Buy	$48
Oct-08-24	Initiated	TD Cowen	Buy
Oct-08-24	Initiated	Stifel	Buy	$47
Oct-08-24	Initiated	Morgan Stanley	Overweight	$35
Oct-08-24	Initiated	Cantor Fitzgerald	Overweight

Oct-27-25 08:30AM	Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology (PR Newswire)
Oct-13-25 07:30AM	Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC (GlobeNewswire)
Aug-27-25 04:01PM	Bicara Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-14-25 09:55AM	Does Bicara Therapeutics Inc. (BCAX) Have the Potential to Rally 187.73% as Wall Street Analysts Expect? (Zacks)
Aug-12-25 07:30AM	Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
04:05PM	Loading…
Jun-11-25 04:05PM	Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors (GlobeNewswire) -5.56%
Jun-03-25 04:01PM	Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire) +11.21%
Jun-01-25 01:12PM	Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025 (GlobeNewswire)
May-29-25 06:54AM	ASCO25: Merus wins in head-to-head with Bicara for head and neck cancer (Clinical Trials Arena)
May-27-25 01:59PM	Morgan Stanley Maintains Buy Rating on Bicara (BCAX) After the Ficerafusp Alfa Trial Update (Insider Monkey) +7.66%
May-26-25 09:14AM	Stifel Reaffirms Buy Rating on BCAX After Promising ASCO Data for HPV-Negative Patients (Insider Monkey)
May-23-25 10:15AM	Merus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara Therapeutics (Investor's Business Daily) -40.80%
May-22-25 05:00PM	Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual Meeting (GlobeNewswire) +7.33%
May-13-25 07:30AM	Bicara Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) -8.10%
Apr-28-25 04:01PM	Bicara Therapeutics Highlights Broad Potential of Ficerafusp Alfa at AACR Annual Meeting 2025 (GlobeNewswire)
10:00AM	Loading…
Apr-23-25 10:00AM	Bicara Therapeutics to Present Updated Data from Ongoing Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) +12.23%
Apr-19-25 06:22AM	Bicara: Innovative Precision Tumor Targeting (Seeking Alpha)
Mar-27-25 07:30AM	Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Mar-25-25 04:45PM	Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025 (GlobeNewswire) -5.58%
Feb-24-25 04:01PM	Bicara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-11-25 04:01PM	Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (GlobeNewswire)
Jan-27-25 08:00AM	Bicara Therapeutics Presents Phase 1/1b Dose Expansion Results with Ficerafusp Alfa in Advanced Squamous Cancer of the Anal Canal at the 2025 ASCO Gastrointestinal Cancers Symposium (GlobeNewswire)
Jan-08-25 10:16AM	Early success for MBX in Phase I trial of GLP-1RA for hypoglycaemia (Clinical Trials Arena)
Nov-12-24 07:30AM	Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -7.30%
Nov-11-24 04:01PM	Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference (GlobeNewswire)
Oct-14-24 06:45AM	Opening Day: Another trio of biotech IPOs make Friday debut (TipRanks)
Oct-08-24 10:44AM	MBX Biosciences earns Buy rating at three investment firms (Investing.com) -7.77%
Sep-23-24 07:05PM	RA Capital Management's Strategic Acquisition of Bicara Therapeutics Shares (GuruFocus.com)
Sep-19-24 01:13AM	TPG GP A, LLC Acquires New Stake in Bicara Therapeutics Inc (GuruFocus.com)
Sep-18-24 03:01PM	FMR LLC Acquires New Stake in Bicara Therapeutics Inc (GuruFocus.com)
09:13AM	Loading…
Sep-17-24 09:13AM	Bicara Therapeutics closes $362m IPO in flurry of biotech listing activity (Pharmaceutical Technology) +6.53%
Sep-16-24 04:01PM	Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) +8.54%
Sep-13-24 04:09PM	Biotech IPO Shares Climb in Debuts After Deals Upsized (Bloomberg)
12:19AM	Bicara Leads Trio of US Biotech IPOs Raising $703 Million (Bloomberg)
Sep-12-24 09:15PM	Bicara Therapeutics Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)
07:02PM	Three biotechs raise $700M in rare burst of IPO activity (BioPharma Dive)

Bicara Therapeutics, Inc. is a clinical-stage biotechnology company and develops biologics engineered to combine the precision of well validated, tumor-targeting antibodies with the power of tumor microenvironment modulators. The company's bi-functional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Its products include BCA101, a first-in-class EGFR/TGF-ß-trap bifunctional antibody in clinical development for multiple tumor types. The company was founded on December 12, 2018 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cohlhepp Ryan	President and COO	Oct 15 '25	Option Exercise	3.79	8,000	30,318	210,641	Oct 16 04:41 PM
Cohlhepp Ryan	President and COO	Oct 15 '25	Sale	18.16	12,500	226,942	198,141	Oct 16 04:41 PM
Mazumdar Claire	Officer	Oct 16 '25	Proposed Sale	18.83	24,103	453,761		Oct 16 04:13 PM
Mazumdar Claire	Chief Executive Officer	Oct 15 '25	Option Exercise	3.79	13,289	50,363	323,181	Oct 15 06:00 PM
Mazumdar Claire	Chief Executive Officer	Oct 13 '25	Option Exercise	3.79	11,445	43,374	321,337	Oct 15 06:00 PM
Mazumdar Claire	Chief Executive Officer	Oct 15 '25	Sale	18.84	13,289	250,391	309,892	Oct 15 06:00 PM
Mazumdar Claire	Chief Executive Officer	Oct 13 '25	Sale	18.92	11,445	216,545	309,892	Oct 15 06:00 PM
Cohlhepp Ryan	Officer	Oct 15 '25	Proposed Sale	18.13	12,500	226,601		Oct 15 04:20 PM
Mazumdar Claire	Officer	Oct 15 '25	Proposed Sale	18.84	13,289	250,391		Oct 15 04:18 PM
Mazumdar Claire	Officer	Oct 13 '25	Proposed Sale	18.92	11,445	216,545		Oct 14 09:05 AM
Raben David	Chief Medical Officer	Oct 09 '25	Option Exercise	3.79	22,000	83,376	57,497	Oct 10 05:23 PM
Raben David	Chief Medical Officer	Oct 09 '25	Sale	18.45	22,000	405,900	35,497	Oct 10 05:23 PM
Hyep Ivan	Chief Financial Officer	Oct 09 '25	Option Exercise	3.79	6,415	24,312	151,770	Oct 10 05:22 PM
Hyep Ivan	Chief Financial Officer	Oct 09 '25	Sale	18.23	6,415	116,931	145,355	Oct 10 05:22 PM
Hyep Ivan	Officer	Oct 09 '25	Proposed Sale	17.89	6,415	114,764		Oct 09 04:31 PM
Raben David	Officer	Oct 09 '25	Proposed Sale	18.45	22,000	405,900		Oct 09 04:08 PM
Hyep Ivan	Chief Financial Officer	Oct 07 '25	Option Exercise	3.79	18,244	69,141	163,599	Oct 08 05:33 PM
Hyep Ivan	Chief Financial Officer	Oct 06 '25	Option Exercise	3.79	6,514	24,687	151,869	Oct 08 05:33 PM
Hyep Ivan	Chief Financial Officer	Oct 08 '25	Option Exercise	3.79	5,627	21,325	150,982	Oct 08 05:33 PM
Hyep Ivan	Chief Financial Officer	Oct 07 '25	Sale	18.22	18,244	332,386	145,355	Oct 08 05:33 PM
Hyep Ivan	Chief Financial Officer	Oct 06 '25	Sale	18.17	6,514	118,356	145,355	Oct 08 05:33 PM
Hyep Ivan	Chief Financial Officer	Oct 08 '25	Sale	18.21	5,627	102,456	145,355	Oct 08 05:33 PM
Cohlhepp Ryan	President and COO	Oct 06 '25	Option Exercise	3.79	24,000	90,955	245,141	Oct 08 05:33 PM
Cohlhepp Ryan	President and COO	Oct 07 '25	Option Exercise	3.79	8,000	30,318	213,541	Oct 08 05:33 PM
Cohlhepp Ryan	President and COO	Oct 06 '25	Sale	18.06	39,600	714,998	205,541	Oct 08 05:33 PM
Cohlhepp Ryan	President and COO	Oct 07 '25	Sale	18.06	10,900	196,844	202,641	Oct 08 05:33 PM
Hyep Ivan	Officer	Oct 08 '25	Proposed Sale	18.17	5,627	102,242		Oct 08 04:04 PM
Hyep Ivan	Officer	Oct 07 '25	Proposed Sale	18.00	18,244	328,392		Oct 07 04:20 PM
Cohlhepp Ryan	Officer	Oct 07 '25	Proposed Sale	18.00	10,900	196,200		Oct 07 04:07 PM
Cohlhepp Ryan	Officer	Oct 06 '25	Proposed Sale	18.06	39,600	714,997		Oct 06 04:36 PM
Hyep Ivan	Officer	Oct 06 '25	Proposed Sale	17.04	6,514	110,998		Oct 06 04:07 PM
Meisner Lara	Chief Legal Officer	Sep 29 '25	Option Exercise	9.24	33,807	312,495	33,807	Oct 01 04:57 PM
Meisner Lara	Chief Legal Officer	Sep 29 '25	Sale	14.75	33,807	498,653	0	Oct 01 04:57 PM
LARA MEISNER	Officer	Sep 29 '25	Proposed Sale	11.71	33,807	395,880		Sep 29 04:38 PM
Meisner Lara	Chief Legal Officer	Sep 15 '25	Option Exercise	5.45	15,829	86,268	15,829	Sep 17 05:01 PM
Meisner Lara	Chief Legal Officer	Sep 15 '25	Sale	11.49	15,829	181,875	0	Sep 17 05:01 PM
Meisner Lara	Chief Legal Officer	Jun 16 '25	Option Exercise	5.45	15,829	86,268	15,829	Jun 18 05:12 PM
Meisner Lara	Chief Legal Officer	Jun 16 '25	Sale	10.43	15,829	165,096	0	Jun 18 05:12 PM
LARA S. MEISNER	Officer	Jun 16 '25	Proposed Sale	10.84	31,658	343,173		Jun 16 04:29 PM
Meisner Lara	Chief Legal Officer	Mar 14 '25	Option Exercise	5.45	79,146	431,346	79,145	Mar 18 06:35 PM
Meisner Lara	Chief Legal Officer	Mar 14 '25	Sale	12.90	79,146	1,021,211	0	Mar 18 06:35 PM
LARA S. MEISNER	Officer	Mar 14 '25	Proposed Sale	13.35	79,146	1,056,599		Mar 14 04:21 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BCAX

Bicara Therapeutics Inc

Upgrade your FINVIZ experience